Compare BURL & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BURL | BMRN |
|---|---|---|
| Founded | 1972 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Department/Specialty Retail Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.0B | 13.0B |
| IPO Year | 2013 | 1999 |
| Metric | BURL | BMRN |
|---|---|---|
| Price | $234.55 | $64.85 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 16 | 18 |
| Target Price | ★ $355.29 | $88.22 |
| AVG Volume (30 Days) | 1.7M | ★ 1.7M |
| Earning Date | 05-28-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 21.92 | N/A |
| EPS | ★ 4.67 | 0.77 |
| Revenue | ★ $11,566,910,000.00 | $1,313,646,000.00 |
| Revenue This Year | $12.72 | $15.02 |
| Revenue Next Year | $8.47 | $12.23 |
| P/E Ratio | ★ $48.67 | $83.70 |
| Revenue Growth | 8.76 | ★ 17.62 |
| 52 Week Low | $236.28 | $49.26 |
| 52 Week High | $378.33 | $70.98 |
| Indicator | BURL | BMRN |
|---|---|---|
| Relative Strength Index (RSI) | 17.14 | 47.58 |
| Support Level | N/A | $64.07 |
| Resistance Level | $317.57 | $66.99 |
| Average True Range (ATR) | 11.25 | 1.52 |
| MACD | -3.89 | -0.32 |
| Stochastic Oscillator | 0.47 | 21.25 |
Burlington Stores Inc is an off-price retailer offering an extensive selection of in-season, fashion-focused merchandise, including women's ready-to-wear apparel, menswear, youth apparel, baby, beauty, footwear, accessories, home, toys, gifts, and coats. The company sells a broad selection of desirable, first-quality, current-brand, labeled merchandise acquired directly from nationally recognized manufacturers and other suppliers. It sells products in categories such as Ladies apparel, Accessories and shoes, Home, Mens apparel, Kids apparel and baby, and Outerwear.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.